SKK
ANIK icon

Shepherd Kaplan Krochuk’s Anika Therapeutics ANIK Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-6,379
Closed -$296K – 557
2014
Q2 		$296K Buy
6,379
+105
+2% +$4.67K 0.03% 359
2014
Q1 		$258K Buy
+6,274
New +$233K 0.03% 385

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thompson Siegel & Walmsley
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Gotham Asset Management
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Shepherd Kaplan Krochuk's ANIK Position: Q3 2014 in Review

Shepherd Kaplan Krochuk sold out of Anika Therapeutics (ANIK) in Q3 2014, closing a stake of 6,379 shares — an estimated $296K sold.

Shepherd Kaplan Krochuk first reported a position in ANIK in Q1 2014 and held it in 2 quarters. The position peaked at $296K in Q2 2014. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

  • Shepherd Kaplan Krochuk reported no remaining Anika Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 6,379 Anika Therapeutics shares in Q3 2014, an estimated $296K.
  • Shepherd Kaplan Krochuk first reported a position in Anika Therapeutics in Q1 2014 and held it in 2 quarters.
  • Shepherd Kaplan Krochuk's Anika Therapeutics position peaked at $296K in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on Shepherd Kaplan Krochuk's 13F filing for Q3 2014, filed 13 Nov 2014.